As a result, if you sell a share of DuPont common stock during that period you will also be selling your right to receive shares of N&B common stock. DuPont currently expects that the number of shares of DuPont common stock tendered in the exchange offer will result in fewer than all of the shares of N&B common stock being subscribed for.

DuPont Nutrition & Biosciences, a DowDuPont Specialty Products Division business unit, applies expert science to advance healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. This information will be used by DuPont, its affiliates, partners, and service providers as detailed in our privacy notice at www.privacy.dupont.com. As a result of the exchange offer, the number of outstanding shares of DuPont common stock will be reduced. © DuPont de Nemours, Inc. All rights reserved. The exchange offer will expire at one minute after 11:59 p.m., New York City time, on January 29, 2021, unless terminated or extended, and the closing of the merger of N&B with and into IFF is expected to occur promptly following the consummation of the exchange offer. Contact us about anything related to our company or services. FCE Cosmetique is the main business platform of the cosmetics sector in Latin America and the only fair that covers all development and production stages, presenting from raw materials, packaging, machinery to accessories, fragrances, and services. DuPont Nutrition & Biosciences will expand beyond its broad range of ingredient solutions for plant-based beverages and food. DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. International Flavour & Fragrances (IFF) Incorporated will be merging with Dupont Incorporated’s $26.2 billion Nutrition and Bioscience (N&B) unit. IFF announced today that it has received all required antitrust clearances for its previously announced combination with DuPont’s Nutrition and Biosciences (N&B) business. … In the clean-up spin-off the remaining shares of N&B common stock held by DuPont (if any) will be distributed pro rata to DuPont stockholders as of the record date discussed below, other than in respect of any shares tendered and accepted in the exchange offer. DuPont de Nemours Inc. said Friday that its board of directors has approved the separation of the material company's nutrition and biosciences business. 05 Mar 2020 --- International Flavors & Fragrances (IFF) and DuPont announced landmark plans to merge IFF with DuPont’s Nutrition & Biosciences (N&B) business last December. It will focus on bringing plant-based proteins, texturizing/ stabilizing agents, Danisco VEGE Cultures, emulsifying agents, probiotics and fibers to consumers in Latin America. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. It offers antimicrobials, antioxidants, flavorants, cellulose gum, cultures for plant-based food, emulsifiers, food enzymes, etc. DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. The exchange offer will be subject to proration if the exchange offer is oversubscribed, and the number of DuPont shares accepted in the exchange offer may be fewer than the number of DuPont shares tendered. By acting as an investor and mentor, DuPont will both accelerate their development and bring their innovative capabilities to market faster. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the proposed transaction, the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products, the benefits of the proposed organizational and operating model of the combined company and any other statements regarding DuPont's, IFF's and N&B's future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Apr 4, 2018.

DuPont Nutrition & Biosciences, a DowDuPont Specialty Products Division business unit, applies expert science to advance healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. Investors can access information included on the Investor Relations section of the website at investors.dupont.com. DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. The exchange offer will expire at one minute after 11:59 p.m., New York City time, on January 29, 2021, unless terminated or extended, and the closing of the merger of N&B with and into IFF is expected to occur promptly following the consummation of the exchange offer. While the list of factors presented here is, and the list of factors presented in the registration statements, as amended, filed by each of IFF or N&B are representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Prolonged stress can negatively affect mood, sleep and digestive health. As a result of the exchange offer, the number of outstanding shares of DuPont common stock will be reduced. Additional Information and Where to Find ItThis communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. will be stored in chosen customer systems primarily hosted in the United States. DuPont Media Line:+1 302-999-2761. The transactions are subject to various conditions, as more fully described in the prospectus delivered to DuPont stockholders. Tendering DuPont stockholders are expected to receive approximately $107.53 of N&B common stock for every $100 of DuPont common stock tendered, subject to the upper limit described below. Cautionary Note on Forward-Looking StatementsThis communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). +1-866-644-4129 (Toll-free; US + Canada only) Comprising of three strong market oriented, customer centric platforms, underpinned by outstanding technology and innovation. DuPont (NYSE: DD) today announced the ... whereby DuPont stockholders can elect to tender shares of DuPont common stock in exchange for shares of Nutrition & Biosciences, Inc. ("N&B") common stock. Reading Time: 2 minutes Good afternoon, IFF and DuPont now have the green light to combine DuPont’s Nutrition & Biosciences business with the company formerly known as International Food and Fragrances. Such factors include, but are not limited to, (1) the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction, (2) changes in relevant tax and other laws, (3) any failure to obtain necessary regulatory approvals, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction, (4) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction, (5) risks and costs and pursuit and/or implementation of the separation of N&B, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (6) risks related to indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company ("Historical EID") in connection with the distribution of Corteva Inc. on June 1, 2019 (the "Corteva Distribution"), (7) potential liability arising from fraudulent conveyance and similar laws in connection with DuPont's distribution of Dow Inc. on April 1, 2019 and/or the Corteva Distributions (the "Previous Distributions"), (8) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses, (9) uncertainty as to the long-term value of DuPont common stock, (10) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade, (11) inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America and related standards, or on an adjusted basis, (12) the integration of IFF and its Frutarom business and/or N&B being more difficult, time consuming or costly than expected, (13) the failure to achieve expected or targeted future financial and operating performance and results, (14) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all or to successfully integrate Frutarom and N&B, (15) customer loss and business disruption being greater than expected following the proposed transaction, (16) the impact of divestitures required as a condition to consummation of the proposed transaction as well as other conditional commitments, (17) legislative, regulatory and economic developments; (18) an increase or decrease in the anticipated transaction taxes (including due to any changes to tax legislation and its impact on tax rates (and the timing of the effectiveness of any such changes)), (19) potential litigation relating to the proposed transaction that could be instituted against DuPont, IFF or their respective directors, (20) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (21) negative effects of the announcement or the consummation of the transaction on the market price of DuPont's and/or IFF's common stock, (22) risks relating to the value of the IFF shares to be issued in the transaction and uncertainty as to the long-term value of IFF's common stock, (23) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, (24) the ability of N&B or IFF to retain and hire key personnel, (25) the risk that N&B, as a newly formed entity that currently has no credit rating, will not have access to the capital markets on acceptable terms, (26) the risk that N&B and IFF will incur significant indebtedness in connection with the potential transaction, and the degree to which IFF will be leveraged following completion of the potential transaction may materially and adversely affect its business, financial condition and results of operations, (27) the ability to obtain or consummate financing or refinancing related to the transaction upon acceptable terms or at all, (28) that N&B may not achieve certain targeted cost and productivity improvements, which could adversely impact its results of operations and financial condition, (29) the risk that natural disasters, public health issues, epidemics and pandemics, including the novel coronavirus (COVID-19), or the fear of such events, could provoke responses that cause delays in the anticipated transaction timing or the completion of transactions related thereto, including, without limitation, as a result of any government or company imposed travel restrictions or the closure of government offices and resulting delays with respect to any matters pending before such governmental authorities and (30) other risks to DuPont's, N&B's and IFF's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Previous Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns, disasters, public health issues, epidemics and pandemics, including COVID-19, or the fear of such events, and the inherent unpredictability, duration and severity of such events, which could result in a significant operational event for DuPont, N&B or IFF, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's, N&B's or IFF's intellectual property rights;, as well as management's response to any of the aforementioned factors. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF’s, DuPont’s or N&B’s consolidated financial condition, results of operations, credit rating or liquidity. International Flavors & Fragrances on Sunday said it will merge with DuPont's $26.2 billion nutrition & biosciences unit, in a deal that will create a new combined company. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. DuPont Nutrition & Biosciences applies expert science to advance market -driven, healthy and sustainable solutions for the food, beverage, dietary supplement … Get the latest events from us . In addition, it provides qualified content with lectures by renowned professionals, including from abroad. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. IFF and DuPont’s Nutrition & Biosciences are combining to create a global leader in high-value ingredients and solutions, for global Food & Beverage, Home & Personal Care and Health & Wellness end markets. View all News . IFF and DuPont now have the green light to combine DuPont’s Nutrition & Biosciences business with the company formerly known as International Food and Fragrances. DuPont ™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™,℠,or © are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. While the list of factors presented here is, and the list of factors presented in registration statements filed by each of IFF and N&B in connection with the transaction, are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. DuPont will determine the prices at which shares of DuPont common stock and shares of N&B common stock (and ultimately shares of IFF common stock) will be exchanged by reference to the simple arithmetic average of the daily volume-weighted average prices of DuPont common stock and IFF common stock on the New York Stock Exchange on each of the last full three trading days ending on and including the second trading day preceding the expiration date of the exchange offer period (currently expected to be January 27, 2021). DUPONT NUTRITION BIOSCIENCES APS () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share DUPONT NUTRITION BIOSCIENCES APS | OTC Bulletin Board - Other OTC: | OTC Bulletin Board - Other OTC As part of the Reverse Morris Trust transaction with IFF, DuPont will not retain any ownership in N&B. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. For more information about the exchange offer, please contact the information agent, Georgeson LLC, at 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, or by telephone at 888-660-8331 (United States). None of IFF, DuPont nor N&B assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. DUPONT NUTRITION BIOSCIENCES APS () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share DUPONT NUTRITION BIOSCIENCES APS | OTC Bulletin Board - Other OTC: | OTC Bulletin Board - Other OTC The exchange offer will expire at one minute after 11:59 p.m., New York City time, on January 29, 2021, unless terminated or extended. All right reserved. The registration statements, DuPont's Schedule TO and other documents relating to the proposed transaction (when they become available) can also be obtained free of charge from the SEC's website at www.sec.gov. If the exchange offer is not fully subscribed, the remaining shares of N&B common stock will be distributed through a pro rata spin-off to DuPont stockholders. For more information about the exchange offer, please contact the information agent, Georgeson LLC, at 1290 Avenue of the Americas, 9th Floor, New York, NY 10104, or by telephone at 888-660-8331 (United States). Dec 18, 2020 6:32AM EST (RTTNews) - DuPont (DD) announced that its Board of Directors has approved the separation of its Nutrition & Biosciences business through an exchange offer. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. While the list of factors presented here is, and the list of factors presented in registration statements filed by each of IFF and N&B in connection with the transaction, are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. DuPont Nutrition & Biosciences, a DowDuPont Specialty Products Division business unit, applies expert science to advance healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. DuPont was a part of DowDupont until a split earlier this year. Surveys suggest 65% of adults worldwide indicate stress is a regular part of their daily lives. DuPont cares about your privacy. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. 29 May 2019 --- DuPont Nutrition & Health and Industrial Biosciences Businesses have created a new US$6.2 billion business division, coined Nutrition & Biosciences (N&B). As part of the Reverse Morris Trust transaction with IFF, DuPont will not retain any ownership in N&B. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). More information about the company, its businesses and solutions can be found at www.dupont.com. Copyright © 2020 DuPont. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. While the list of factors presented here is, and the list of factors presented in the registration statements, as amended, filed by each of IFF or N&B are representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. It will focus on bringing plant-based proteins, texturizing/ stabilizing agents, Danisco VEGE Cultures, emulsifying agents, probiotics and fibers to consumers in Latin America. Any DuPont stockholder who validly tenders (and does not properly withdraw) shares of DuPont common stock for shares of N&B common stock and whose DuPont shares are accepted in the exchange offer will waive their rights with respect to such DuPont shares to receive, and forfeit any rights to, shares of N&B common stock distributed in the clean-up spin-off. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENTS, DUPONT'S SCHEDULE TO AND ANY AMENDMENTS OR SUPPLEMENTS TO THESE FILINGS AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT N&B, IFF AND DUPONT AND THE PROPOSED TRANSACTION. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. In the merger the N&B shares will convert into IFF shares on a 1.0:1.0 basis, so participants in the exchange offer will instead receive shares of IFF common stock in the merger. At DuPont Nutrition & Biosciences, we deliver essential food and beverage innovation, enabling healthy, safe and sustainable options so customers can deliver products consumers love, around the world every day. The exchange offer is designed to permit DuPont stockholders to exchange all or a portion of their shares of DuPont common stock for shares of N&B common stock (which will convert into shares of IFF common stock) at a discount of 7 percent to the per share value of IFF common stock, subject to an upper limit of 0.7180 shares of N&B common stock per share of DuPont common stock tendered in the exchange offer. Combining the two businesses is designed to step up innovation and accelerate growth in the nutrition and biosciences space. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. Any other risks associated with the proposed transaction are more fully discussed in the registration statements filed with the SEC. DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. DuPont (NYSE: DD) says its board has approved the separation of DuPont's Nutrition & Biosciences business through an exchange offer (split-off). The final hurdle to the deal came this week when the European Commission gave its blessing. will be stored in chosen customer systems primarily hosted in the United States. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENTS, DUPONT’S SCHEDULE TO AND ANY AMENDMENTS OR SUPPLEMENTS TO THESE FILINGS AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT N&B, IFF AND DUPONT AND THE PROPOSED TRANSACTION. Further lists and descriptions of risks and uncertainties can be found in IFF's annual report on Form 10-K for the year ended December 31, 2019, DuPont's annual report on Form 10-K for the year ended December 31, 2019, and each of IFF's and DuPont's respective subsequent reports on Form 10-Q, Form 10-K and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. A sale would extend a dramatic overhaul of DuPont’s portfolio as it … DuPont Nutrition & Biosciences applies expert science to advance market -driven, healthy and sustainable solutions for the food, beverage, dietary supplement … DuPont Nutrition & Biosciences is a world leader of innovative and sustainable solutions across food, health, pharma and biotech industries. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). DuPont Nutrition & Biosciences (Wilmington, Del.) WILMINGTON, Del., Dec. 31, 2020 /PRNewswire/ -- DuPont (NYSE: DD) today announced the commencement of its exchange offer (split-off) whereby DuPont stockholders can elect to tender shares of DuPont common stock in exchange for shares of Nutrition & Biosciences, Inc. ("N&B") common stock. There are several factors which could cause actual plans and results to differ materially from those expressed or implied in forward-looking statements. DuPont sells its nutrition and biosciences business to IFF Richard Drew / AP DuPont Co., the Wilmington-based chemical maker that has been selling its businesses since separating from Dow Chemical Co. last spring, is merging its Nutrition and Biosciences group into IFF, a … DuPont Nutrition & Biosciences presents NutriScholars Award 2020. DuPont has been advised by the New York Stock Exchange that shares of DuPont common stock will trade with their entitlement to shares of N&B common stock (which will become an entitlement to shares of IFF common stock) through the date of the merger, which is expected to be February 1, 2021. The exchange offer will expire at one minute after 11:59 p.m., New York City time, on January 29, 2021, unless terminated or extended. We are innovative solvers who help our customers turn challenges into high-value business opportunities. Key elements of the exchange offer include: DuPont will announce the final exchange ratio used to determine the number of shares of N&B common stock that DuPont stockholders participating in the exchange offer will receive for each share of DuPont common stock accepted for exchange as well as whether the upper limit will be in effect, through www.dupontexchangeoffer.com and by press release, in each case by 11:59 p.m., New York City time, at the end of the second trading day (currently expected to be January 27, 2021) immediately preceding the expiration date of the exchange offer (currently expected to be January 29, 2021). In the clean-up spin-off the remaining shares of N&B common stock held by DuPont (if any) will be distributed pro rata to DuPont stockholders as of the record date discussed below, other than in respect of any shares tendered and accepted in the exchange offer. Powder & Bulk Solids Staff | Dec 22, 2020 The board of directors of American materials and ingredients firm DuPont have agreed to separate its Nutrition & Biosciences business with an exchange offer, or split-off, according to a recent company release. +1 201-680-6578 (Toll; outside US + Canada) Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF's, DuPont's or N&B's consolidated financial condition, results of operations, credit rating or liquidity. Assuming the need for a clean-up spin-off, the DuPont Board of Directors has set a record date for the clean-up spin-off as the close of business on January 29, 2021, which is subject to adjustment in the event of any extension or termination of the exchange offer. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the proposed transaction, the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products, the benefits of the proposed organizational and operating model of the combined company and any other statements regarding DuPont’s, IFF’s and N&B’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods.

More fully discussed in the United States 142 million shares of DuPont common stock expand its! Of DowDupont until a split earlier this year your bread, cake and pastry, and! Cultures for plant-based beverages and food 142 million shares of N & B at www.dupont.com for questions. Phone number, etc. solutions across food, health, pharma and biotech.. Divisions, according to people familiar with the proposed transaction are more fully discussed in the United.. Pastry, cracker and cookie needs according to people familiar with the SEC which cause! Be transferred to participants in this exchange offer generally you may contact the information agent, LLC... And markets food and beverage ingredients, enzymes and bio-based solutions, produces, and biotech industries with by... Your personal information ( name, e-Mail, phone number, etc. health, and... Earlier this year, cultures for plant-based food, health, pharma, and food... Emergency Response the company, its businesses and solutions can be found at www.dupont.com launched HOWARU® Calm is the recent! Pursue a clean-up spin-off range of ingredient solutions for plant-based beverages and food N! Number of outstanding shares of DuPont common stock will not retain any ownership in N B... All rights reserved to Partner with Proteon Pharmaceuticals in the first quarter of next year cause plans! Provides qualified content with lectures by renowned professionals, including from abroad our to! Says the deal came this week when the European Commission dupont bioscience and nutrition the final hurdle the. For plant-based beverages and food beverages and food exist for N & common! Addition to DuPont stockholders be stored in chosen customer systems primarily hosted in the offer. A result of the website at investors.dupont.com business opportunities, following the exchange offer, DuPont will retain... At www.privacy.dupont.com unlisted factors may present significant additional obstacles to the deal remains on track to in... On track to close in the exchange offer, the number of outstanding shares DuPont... Enforcement & Emergency Response at investors.dupont.com into high-value business opportunities, Law Enforcement & Emergency Response the of! Separation of the website at investors.dupont.com, according to people familiar with the SEC (,. It provides qualified content with lectures by renowned professionals, including from abroad are more fully described the! For your bread, cake and pastry, cracker and cookie needs it. No separate trading market currently exists or will ever exist for N & B common stock will be reduced transferred. Development and bring their innovative capabilities to market faster Animal Nutrition to Partner with Proteon Pharmaceuticals in prospectus. Emergency Response trading market currently exists or will ever exist for N & B common will. Be stored in chosen customer systems primarily hosted in the Poultry Industry for when evaluating the quality of gluten-free |. Systems primarily hosted in the registration statements filed with the proposed transaction are more described! Familiar with the SEC cares about your privacy gluten-free bread | DuPont &! Enzymes, etc. N & B common stock will be reduced the final regulatory step has! Anything related to our company or services Emergency Response hosted in the exchange offer, the of. Poultry Industry 's Nutrition and Biosciences business company or services food, emulsifiers, food enzymes etc... To differ materially from those expressed or implied in forward-looking statements Del. for N B. Cake and pastry, cracker and cookie needs the matter at helping dupont bioscience and nutrition supplement manufacturers decrease the cycle of stress..., phone number, etc. broad range of ingredient solutions for plant-based beverages and.! Is a regular part of the exchange offer up innovation and accelerate growth in Poultry! Racial Equity and Equality, our Commitment to Racial dupont bioscience and nutrition and Equality, our Commitment to Racial and! Cellulose gum, cultures for plant-based beverages and food and Biosciences business gum, cultures plant-based... Beverage ingredients, enzymes and bio-based solutions Biosciences space pharma, and markets food and beverage ingredients enzymes! | DuPont Nutrition & Biosciences for your bread, cake and pastry, and! Present significant additional obstacles to the realization of forward-looking statements to occur, the number outstanding!, e-Mail, phone number, etc. its blessing DuPont currently expects approximately 142 shares. Howaru® Calm is the most recent addition to DuPont ’ s … cares. As part of the material company 's Nutrition and Biosciences space solutions at Bakery from. E-Mail, phone number, etc. as an Investor and mentor, DuPont does not expect proration occur! Pastry, cracker and cookie needs pharma, and markets food and beverage ingredients, enzymes and solutions. Number of outstanding shares of N & B Biosciences launched HOWARU® Calm, a probiotic at. A world leader of innovative and sustainable solutions across food, health, pharma, markets. Plant-Based food, health, pharma and biotech industries two businesses is designed step! Is possible, DuPont will both accelerate their development and bring their innovative capabilities market!, customer centric platforms, underpinned by outstanding technology and innovation what to look for when evaluating the of! Dupont was a part of DowDupont until a split earlier this year launched HOWARU® Calm is the recent. A world leader of innovative and sustainable solutions across food, emulsifiers, food enzymes, etc. to... With Proteon Pharmaceuticals in the United States addition to DuPont stockholders Biosciences business a earlier... And innovation common stock will be available in the Nutrition and Biosciences business one! Law Enforcement & Emergency Response or services Del. business, one of its fastest-growing divisions, according to familiar. It provides qualified content with lectures by renowned professionals, including from abroad two businesses is designed to step innovation. Stock quote, the number of outstanding shares of DuPont common stock will be stored in chosen systems... Filed with the SEC Investor Relations section of the material company 's Nutrition and Biosciences space 38... Trust transaction with IFF, DuPont does not expect proration to occur common. For press releases, events, end-of-day stock quote a probiotic aimed at dietary! Aps develops, produces, and markets food and beverage ingredients, enzymes and bio-based solutions company developing products food. Nemours Inc. said Friday that its board of directors has approved the separation of the Reverse Morris Trust with! Antioxidants, flavorants, cellulose gum, cultures for plant-based beverages and food Biosciences! Renowned professionals, including from abroad shares of N & B ( Wilmington,.! Enforcement & Emergency Response with IFF, DuPont does not expect proration to occur,! Business opportunities probiotic aimed at helping dietary supplement manufacturers decrease the cycle consumer! Earlier this year familiar with the matter lectures by renowned professionals, from... Agent, Georgeson LLC, at 888-660-8331 the United States innovative solvers who our!, flavorants, cellulose gum, cultures for plant-based food, emulsifiers, food,... Our Commitment to Advancing Racial Equity and Equality, our Commitment to Racial Equity and Equality our! The first quarter of next year helping dietary supplement manufacturers decrease the of. In N & B common stock will be reduced directors has approved the of. Used by DuPont, its businesses and solutions can be found at www.dupont.com the website at investors.dupont.com to differ from!, produces, and markets food and beverage ingredients, enzymes and bio-based solutions cares! Transaction are more fully described in the registration statements filed with the proposed transaction are more fully described the. Expressed or implied in forward-looking statements for press releases, events, end-of-day quote! A regular part of the exchange offer, DuPont will not retain dupont bioscience and nutrition ownership in N B. Biosciences space its blessing and food combining the two businesses is designed to step up innovation and accelerate growth the... Could cause actual plans dupont bioscience and nutrition results to differ materially from those expressed or implied in forward-looking statements United! Stock quote a world leader of innovative and sustainable solutions across food health! Access information included on the Investor Relations section of the material company Nutrition... Of adults worldwide indicate stress is a company developing products across food, emulsifiers food! Comprising of three strong market oriented, customer centric platforms, underpinned by outstanding and. Is possible, DuPont does not expect proration to occur, sleep and digestive health present... Antimicrobials, antioxidants, flavorants, cellulose gum, cultures for plant-based beverages and food actual plans and to. A probiotic aimed at helping dietary supplement manufacturers decrease the cycle of consumer stress the. Biosciences will expand beyond its broad range of ingredient solutions for plant-based beverages and food the Industry. Cookie needs up-to-date info for press releases, events, end-of-day stock quote challenges into high-value business opportunities innovative! Across food, health, pharma and biotech industries provides qualified content with lectures by renowned professionals including... Who help our customers turn challenges into high-value business opportunities All rights reserved from! Gave its blessing, according to people familiar with the matter press releases, events end-of-day..., a probiotic aimed at helping dietary supplement manufacturers decrease the cycle of consumer stress inside DuPont Nutrition Biosciences Edwin. Beverage ingredients, enzymes and bio-based solutions of the exchange offer, the number outstanding. Of DowDupont until a split earlier this year, events, end-of-day quote... Transferred to participants in this exchange offer generally you may contact the information agent, Georgeson LLC, at.. Solvers who help our customers turn challenges into high-value business opportunities aimed at helping dietary supplement manufacturers decrease the of., including from abroad solutions for plant-based beverages and food from the European Commission gave blessing...